Shares of Rocket Pharmaceuticals Inc (NASDAQ:RCKT) have been given an average broker rating score of 3.00 (Hold) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold rating.
Zacks has also given Rocket Pharmaceuticals an industry rank of 196 out of 265 based on the ratings given to its competitors.
RCKT has been the subject of several recent analyst reports. ValuEngine raised Rocket Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, January 9th. BidaskClub raised Rocket Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, January 5th.
About Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc, formerly Inotek Pharmaceuticals Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.